FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi ® (lecanemab-irmb) in the US
STOCKHOLM, Jan. 13, 2025 /PRNewswire/ --BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug ...
